BIOL Biolase Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BIOL

Price (delayed)

$0.139

Market cap

$4.52M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$29.44

Enterprise value

$12.77M

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and ...

Highlights
The company's EPS has surged by 93% YoY and by 82% QoQ
BIOL's net income is up by 28% year-on-year and by 18% since the previous quarter
The equity has shrunk by 174% QoQ and by 105% YoY
Sector: Healthcare
Industry: Medical Devices
Website: http://www.biolase.com
Peers: ALGN XRAY PDEX

Key stats

What are the main financial stats of BIOL
Market
Shares outstanding
32.52M
Market cap
$4.52M
Enterprise value
$12.77M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.26
Earnings
Revenue
$49.16M
EBIT
-$18.24M
EBITDA
-$15.44M
Free cash flow
-$15.22M
Per share
EPS
-$29.44
Free cash flow per share
-$11.91
Book value per share
-$0.11
Revenue per share
$38.47
TBVPS
$25.18
Balance sheet
Total assets
$35.1M
Total liabilities
$33.15M
Debt
$14.82M
Equity
-$247,000
Working capital
$5.2M
Liquidity
Debt to equity
-60
Current ratio
1.26
Quick ratio
0.61
Net debt/EBITDA
-0.53
Margins
EBITDA margin
-31.4%
Gross margin
34%
Net margin
-42%
Operating margin
-36.5%
Efficiency
Return on assets
-96.8%
Return on equity
-1,012.4%
Return on invested capital
-73.3%
Return on capital employed
-118.2%
Return on sales
-37.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIOL stock price

How has the Biolase stock price performed over time
Intraday
-7.33%
1 week
-1.97%
1 month
-0.71%
1 year
-99.59%
YTD
-87.61%
QTD
-26.77%

Financial performance

How have Biolase's revenue and profit performed over time
Revenue
$49.16M
Gross profit
$16.72M
Operating income
-$17.94M
Net income
-$20.63M
Gross margin
34%
Net margin
-42%
The operating margin has grown by 30% year-on-year and by 15% since the previous quarter
BIOL's net margin is up by 29% year-on-year and by 17% since the previous quarter
BIOL's operating income is up by 29% year-on-year and by 16% since the previous quarter
BIOL's net income is up by 28% year-on-year and by 18% since the previous quarter

Growth

What is Biolase's growth rate over time

Valuation

What is Biolase stock price valuation
P/E
N/A
P/B
N/A
P/S
0
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.26
The company's EPS has surged by 93% YoY and by 82% QoQ
The equity has shrunk by 174% QoQ and by 105% YoY
The stock's price to sales (P/S) is 100% less than its 5-year quarterly average of 1.0 and 100% less than its last 4 quarters average of 0.1

Efficiency

How efficient is Biolase business performance
BIOL's ROE has shrunk by 101% QoQ
The return on assets has dropped by 53% year-on-year and by 52% since the previous quarter
The company's return on sales rose by 30% YoY and by 15% QoQ
Biolase's ROIC has increased by 18% YoY and by 10% from the previous quarter

Dividends

What is BIOL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIOL.

Financial health

How did Biolase financials performed over time
The company's total assets is 6% higher than its total liabilities
The current ratio has declined by 23% year-on-year and by 10% since the previous quarter
Biolase's quick ratio has increased by 9% YoY
The equity has shrunk by 174% QoQ and by 105% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.